deltatrials
Completed PHASE3 NCT05425745

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

Sponsor: NewAmsterdam Pharma

Updated 14 times since 2022 Last updated: Jun 10, 2025 Started: Jul 25, 2022 Primary completion: May 28, 2024 Completion: May 28, 2024

Listed as NCT05425745, this PHASE3 trial focuses on Dyslipidemias and Familial Hypercholesterolemia and remains completed. Sponsored by NewAmsterdam Pharma, it has been updated 14 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Feb 2023 · 4 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Feb 2024 · 9 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshot~Dec 2024 – ~Jul 2025 · 7 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot

Change History

14 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Dec 2024 — Jul 2025 [monthly]

    Completed PHASE3

  4. Oct 2024 — Dec 2024 [monthly]

    Completed PHASE3

  5. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE3

Show 9 earlier versions
  1. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  2. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  4. May 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  5. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  6. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  7. Oct 2022 — Feb 2023 [monthly]

    Recruiting PHASE3

  8. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  9. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NewAmsterdam Pharma
Data source: NewAmsterdam Pharma

For direct contact, visit the study record on ClinicalTrials.gov .